Use of lactobacillus in prevention of recurrences of Clostridium difficile infection in solid organ transplant recipients

Infectious Diseases in Clinical Practice

Volumn 21, Issue 5, 2013, Pages 292-298

  Deshpande, Abhishek ^a   Pasupuleti, Vinay ^a   Mossad, Sherif B ^a   Budev, Marie ^a   Schmitt, Steven K ^a   Corey, Rebecca ^b   Eghtesad, Bijan ^a   Mawhorter, Steven D ^a   Hernandez, Adrian V ^a   Jain, Anil ^a   Avery, Robin K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

C difficile; Diarrhea; Lactobacillus

Indexed keywords

METRONIDAZOLE; VANCOMYCIN;

ADULT; AGED; CLOSTRIDIUM DIFFICILE INFECTION; ENZYME IMMUNOASSAY; FECES ANALYSIS; FEMALE; GRAFT RECIPIENT; HUMAN; INFECTION PREVENTION; LACTOBACILLUS; LIVER; LIVER TRANSPLANTATION; LUNG; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; RECIPIENT; RETROSPECTIVE STUDY; REVIEW;

EID: 84883559588     PISSN: 10569103     EISSN: 15369943     Source Type: Journal    
DOI: 10.1097/IPC.0b013e31828d7231     Document Type: Review

References (46)

1. Fekety R, McFarland LV, Surawicz CM, et al. Recurrent Clostridium difficile diarrhea: Characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis. 1997;24:324-333
2. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med. 1994;330:257-262
3. Kyne L, Hamel MB, Polavaram R, et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34:346-353
4. O'Brien JA, Lahue BJ, Caro JJ, et al. The emerging infectious challenge of Clostridium difficile-Associated disease in Massachusetts hospitals: Clinical and economic consequences. Infect Control Hosp Epidemiol. 2007;28:1219-1227
5. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433-2441
6. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079-1084
7. Deshpande A, Pant C, Jain A, et al. Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence. Curr Med Res Opin. 2008;24:329-333
8. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-Associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442-2449
9. Dubberke ER, Riddle DJ. Clostridium difficile in solid organ transplant recipients. Am J Transplant. 2009;9(suppl 4):S35-S40
10. Albright JB, Bonatti H, Mendez J, et al. Early and late onset Clostridium difficile-Associated colitis following liver transplantation. Transpl Int. 2007;20:856-866
11. Bunnapradist S, Neri L, Wong W, et al. Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality. Am J Kidney Dis. 2008;51:478-486
12. Niemczyk M, Leszczyniski P, Wyzgal J, et al. Infections caused by Clostridium difficile in kidney or liver graft recipients. Ann Transplant. 2005;10:70-74
13. Riddle DJ, Dubberke ER. Clostridium difficile infection in solid organ transplant recipients. Curr Opin Organ Transplant. 2008;13:592-600
14. Barbut F, Richard A, Hamadi K, et al. Epidemiology of recurrences or reinfections of Clostridium difficile-Associated diarrhea. J Clin Microbiol. 2000;38:2386-2388
15. Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-Associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302-307
16. Kelly CP, LaMont JT. Clostridium difficileVmore difficult than ever. N Engl J Med. 2008;359:1932-1940
17. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-Associated disease: Old therapies and new strategies. Lancet Infect Dis. 2005;5:549-557
18. Wilcox MH, Fawley WN, Settle CD, et al. Recurrence of symptoms in Clostridium difficile infectionVrelapse or reinfection? J Hosp Infect. 1998;38:93-100
19. Aspevall O, Lundberg A, Burman LG, et al. Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital. Antimicrob Agents Chemother. 2006;50:1890-1892
20. D'Souza AL, Rajkumar C, Cooke J, et al. Probiotics in prevention of antibiotic associated diarrhoea: Meta-Analysis. BMJ. 2002;324:1361
21. McFarland LV. Meta-Analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006;101:812-822
22. Van Niel CW, Feudtner C, Garrison MM, et al. Lactobacillus therapy for acute infectious diarrhea in children: A meta-Analysis. Pediatrics. 2002;109:678-684
23. Sang LX, Chang B, Zhang WL, et al. Remission induction and maintenance effect of probiotics on ulcerative colitis: A meta-Analysis. World J Gastroenterol. 2010;16:1908-1915
24. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2001;13:1143-1147
25. Guthmann F, Kluthe C, Buhrer C. Probiotics for prevention of necrotising enterocolitis: An updated meta-Analysis. Klin Padiatr. 2010;222:284-290
26. Dendukuri N, Costa V, McGregor M, et al. Probiotic therapy for the prevention and treatment of Clostridium difficile-Associated diarrhea: A systematic review. CMAJ. 2005;173:167-170
27. Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: Randomised double blind placebo controlled trial. BMJ. 2007;335:80
28. Trejo FM, Minnaard J, Perez PF, et al. Inhibition of Clostridium difficile growth and adhesion to enterocytes by Bifidobacterium supernatants. Anaerobe. 2006;12:186-193
29. Naaber P, Smidt I, Stsepetova J, et al. Inhibition of Clostridium difficile strains by intestinal Lactobacillus species. J Med Microbiol. 2004;53:551-554
30. Parkes GC, Sanderson JD, Whelan K. The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-Associated diarrhoea. Lancet Infect Dis. 2009;9:237-244
31. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: An underappreciated and increasing cause of death and complications. Ann Surg. 2002;235:363-372
32. Adams SD, Mercer DW. Fulminant Clostridium difficile colitis. Curr Opin Crit Care. 2007;13:450-455
33. Gellad ZF, Alexander BD, Liu JK, et al. Severity of Clostridium difficile-Associated diarrhea in solid organ transplant patients. Transpl Infect Dis. 2007;9:276-280
34. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271:1913-1918
35. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: Use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000;31:1012-1017
36. Thomas MR, Litin SC, Osmon DR, et al. Lack of effect of Lactobacillus GG on antibiotic-Associated diarrhea: A randomized, placebo-controlled trial. Mayo Clin Proc. 2001;76:883-889
37. Ferrie S, Daley M. Lactobacillus GG as treatment for diarrhea during enteral feeding in critical illness: Randomized controlled trial. JPEN J Parenter Enteral Nutr. 2011;35(1):43-49
38. Plummer S, Weaver MA, Harris JC, et al. Clostridium difficile pilot study: Effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol. 2004;7:59-62
39. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431-455
40. Land MH, Rouster-Stevens K, Woods CR, et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics. 2005;115:178-181
41. Kunz AN, Fairchok MP, Noel JM. Lactobacillus sepsis associated with probiotic therapy. Pediatrics. 2005;116:517;author reply 517-518
42. Deshpande G, Rao S, Patole S. Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birthweight: A systematic review of randomised controlled trials. Lancet. 2007;369:1614-1620
43. Salminen MK, Tynkkynen S, Rautelin H, et al. The efficacy and safety of probiotic Lactobacillus rhamnosus GG on prolonged, noninfectious diarrhea in HIV patients on antiretroviral therapy: A randomized, placebo-controlled, crossover study. HIV Clin Trials. 2004;5:183-191
44. Mego M, Koncekova R, Mikuskova E, et al. Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Phase II study. Support Care Cancer. 2006;14:285-290
45. Cherifi S, Robberecht J, Miendje Y. Saccharomyces cerevisiae fungemia in an elderly patient with Clostridium difficile colitis. Acta Clin Belg. 2004;59:223-224
46. Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: An emerging infectious disease. Clin Infect Dis. 2005;40:1625-1634